Clinical Trial Transparency – Policy & Medicine

Policy and Medicine Compliance Update May 2023 Issue Features: Regulatory Challenges in Diversity in Clinical Trials, Embracing Generative Artificial Intelligence, Novo Nordisk’s Trans-Atlantic Speech Woes, and The Sixth Circuit Tackles the Meaning of Remuneration in Kickback Cases

Could Simplified Clinical Trials Lead to More Diversity?

Republicans Seek Information on Drugs Approved Based Solely on Clinical Trials Conducted in China

Study Shows that Some Clinical Trial Sponsors are Keeping Results Secret

FDA and NIH Don’t Always Enforce Clinical Trial Transparency Regulations

Whatever the Question, Transparency Isn’t the Answer

New Rule and Guidance Issued on Clinical Trials

Biogen Joins the Center for Therapeutic Target Validation

ICMEJ Proposes Data Socialism – Data Utopianism Has its Cracks – Comments Due April 18

Clinical Trial Transparency: Starting Jan. 1, 2015, European Medicines Agency Will Publish Clinical Reports For New Drugs; Individual Patient Data Next